Veritas Finance Limited Reports Strong Q3FY26 Financial Results

2 min read     Updated on 05 Feb 2026, 06:57 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Veritas Finance Limited reported strong Q3FY26 results with total income from operations of ₹46,182.77 lakhs and net profit after tax of ₹8,175.59 lakhs for the quarter ended December 31, 2025. The nine-month performance showed total income of ₹1,33,042.89 lakhs with net profit after tax of ₹21,106.08 lakhs. The NBFC maintains a debt equity ratio of 2.20 and continues its focus on serving micro and small enterprises with various credit solutions.

31843664

*this image is generated using AI for illustrative purposes only.

Veritas Finance Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating strong operational performance across key financial metrics. The Chennai-based non-banking financial company (NBFC) reported robust growth in both revenue and profitability during the third quarter of fiscal year 2026.

Financial Performance Highlights

The company's financial results showcase consistent growth momentum with total income from operations reaching significant levels during the reporting period.

Metric Q3FY26 (Dec 31, 2025) Q2FY26 (Sep 30, 2025) Q3FY25 (Dec 31, 2024)
Total Income from Operations ₹46,182.77 lakhs ₹43,889.75 lakhs ₹39,970.94 lakhs
Net Profit Before Tax ₹10,856.54 lakhs ₹8,848.46 lakhs ₹9,064.96 lakhs
Net Profit After Tax ₹8,175.59 lakhs ₹6,785.44 lakhs ₹6,893.00 lakhs
Total Comprehensive Income ₹7,901.47 lakhs ₹6,785.45 lakhs ₹6,873.88 lakhs

Nine-Month Performance

For the nine-month period ended December 31, 2025, Veritas Finance demonstrated sustained growth across all major financial parameters.

Parameter Nine Months FY26 Nine Months FY25
Total Income from Operations ₹1,33,042.89 lakhs ₹1,11,856.41 lakhs
Net Profit Before Tax ₹27,859.88 lakhs ₹26,785.22 lakhs
Net Profit After Tax ₹21,106.08 lakhs ₹20,204.06 lakhs
Total Comprehensive Income ₹20,697.20 lakhs ₹20,022.90 lakhs

Capital Structure and Key Ratios

The company maintains a stable capital structure with paid-up equity share capital of ₹13,136.42 lakhs as of December 31, 2025. Net worth stood at ₹3,00,448.02 lakhs, while total capital and outstanding debt reached ₹6,59,604.19 lakhs. The debt equity ratio was recorded at 2.20 for the quarter.

Earnings Per Share Performance

Veritas Finance reported earnings per share of ₹6.23 for the quarter ended December 31, 2025, compared to ₹5.15 in the previous quarter and ₹5.25 in the corresponding quarter of the previous year. For the nine-month period, EPS reached ₹16.08.

Business Operations

Veritas Finance Limited operates as an NBFC registered with the Reserve Bank of India and is classified under the middle layer as per scale-based regulations. The company focuses on extending credit to micro and small enterprises, self-employed businesses, and the salaried segment for business expansion, working capital, house construction, and purchase of used commercial vehicles. The company's debt securities are listed on both BSE and NSE.

Regulatory Compliance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) 34 for interim financial reporting and have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 4, 2026. The results have also been subjected to limited review by the company's statutory auditors.

Historical Stock Returns for Solara Active Pharma Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-1.66%+2.13%-9.55%-14.55%-1.09%-59.83%
Solara Active Pharma Sciences
View Company Insights
View All News
like18
dislike

Solara Active Pharma Sciences Issues Postal Ballot Notice for Director Appointment with E-voting Timeline

4 min read     Updated on 04 Feb 2026, 11:00 PM
scanx
Reviewed by
Jubin VScanX News Team
Overview

Solara Active Pharma Sciences has issued a comprehensive postal ballot notice seeking shareholder approval for appointing Mr. Mohanraj Sanjeevi as Whole-time Director with a three-year term and Rs. 1.00 crore annual remuneration package. The e-voting process runs from February 05 to March 06, 2026, with results expected by March 10, 2026, conducted through CDSL platform in compliance with regulatory requirements.

31771814

*this image is generated using AI for illustrative purposes only.

Solara Active Pharma Sciences Limited has issued a comprehensive postal ballot notice dated February 04, 2026, seeking shareholder approval for the appointment of Mr. Mohanraj Sanjeevi as Whole-time Director, establishing a structured timeline for electronic voting and regulatory compliance.

Postal Ballot Process and Timeline

The company has established a detailed schedule for the postal ballot process, with all communications being conducted electronically in compliance with regulatory requirements under the Companies Act, 2013 and SEBI regulations.

Parameter: Details
Notice Dispatch Date: February 04, 2026
E-voting Commencement: February 05, 2026, at 9.00 A.M. (IST)
E-voting Conclusion: March 06, 2026, at 5.00 P.M. (IST)
Results Declaration: On or before March 10, 2026
Cut-off Date: January 30, 2026

The postal ballot notice has been sent electronically to all members whose names appear in the Register of Members/List of Beneficial Owners as received from depositories as on the cut-off date. The company has appointed Mr. Preetham Hebbar (CoP No. 21431) of M/s. Preetham Hebbar & Co., Practicing Company Secretaries, as the Scrutinizer for conducting the postal ballot e-voting process.

Director Appointment and Regulatory Compliance

The special resolution seeks approval for the appointment of Mr. Mohanraj Sanjeevi (DIN: 08420411) as Whole-time Director (Executive Director) of the Company. The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, had appointed Mr. Sanjeevi as an Additional Director with effect from January 01, 2026, subject to shareholder approval.

Appointment Details: Specifications
Position: Whole-time Director (Executive Director)
Term Duration: Three years (January 01, 2026 to December 31, 2028)
Retirement Clause: Liable to retire by rotation
Regulatory Requirement: Special Resolution under Companies Act, 2013 and SEBI Listing Regulations

Pursuant to Regulation 17(1C) of SEBI Listing Regulations, approval of members is required for board appointments within three months from the date of appointment, necessitating this postal ballot process.

Professional Background and Qualifications

Mr. Mohanraj Sanjeevi brings extensive experience to the role, with over three decades of expertise across pharmaceutical, biotech, defence & aerospace, engineering, apparel, and media sectors. His professional qualifications include deep expertise in industrial relations strategy, workforce governance, statutory and regulatory compliance, and organizational leadership.

Professional Highlights: Details
Industry Experience: 30+ years across multiple sectors
Union Settlements: Successfully negotiated 7-8 long-term settlements
Educational Background: Master's in Social Work (University of Madras), Bachelor's in Behavioural Sciences
Certifications: ISO auditor with industrial relations excellence recognition
Previous Organizations: Mylan Laboratories, The Manipal Group, Tata Advanced Materials

Comprehensive Remuneration Structure

The Board has recommended a structured remuneration package for Mr. Sanjeevi, designed to align with industry standards for similar executive roles.

Component: Amount/Details
Fixed Remuneration: Rs. 85,00,000/- per annum
Variable Pay: Rs. 15,00,000/- per annum
Total Annual Package: Rs. 1,00,00,000/-
Performance Metrics: Individual (50%) and Organizational/BU (50%) performance
Annual Increment: Not exceeding 30% of last drawn remuneration
ESOP Grant: 25,000 stock options at Rs. 375/- per share

The variable pay component will be calculated based on individual performance and organizational/business unit performance metrics. Additional benefits include insurance coverage, leave encashment, travel reimbursement, company car usage, and corporate credit card facility.

E-voting Process and Accessibility

Shareholders can participate in the e-voting process through the platform provided by Central Depository Services (India) Limited (CDSL). The company has ensured compliance with all applicable circulars issued by the Ministry of Corporate Affairs and SEBI regulations.

Voting Access: Method
Demat Shareholders: Through depository accounts (CDSL/NSDL)
Physical Shareholders: Direct access via CDSL e-voting system
Platform Provider: Central Depository Services (India) Limited
Authentication: OTP-based verification for registered mobile/email

Individual shareholders holding securities in demat mode can vote through their demat accounts, while those holding shares in physical form can access the voting platform directly through CDSL's e-voting system using their folio numbers.

Company Financial Context and Strategic Focus

The appointment comes as the company continues implementing various corrective measures to improve financial performance, including product portfolio rationalization with focus on higher-margin products and cost-optimization initiatives.

Financial Performance: 2024-25 2023-24 2022-23
Total Revenue (Rs. Cr.): 1292.90 1294.29 1465.95
Profit/(Loss) After Tax (Rs. Cr.): (1.08) (566.87) (22.21)

The company has witnessed improvement in gross margins and positive EBITDA, with expectations of enhanced productivity levels and gradual improvement in profitability through continued emphasis on efficiency and improved product mix. The resolution, if approved by the requisite majority, will be deemed to have been passed on March 06, 2026, the last date of remote e-voting.

Historical Stock Returns for Solara Active Pharma Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-1.66%+2.13%-9.55%-14.55%-1.09%-59.83%
Solara Active Pharma Sciences
View Company Insights
View All News
like20
dislike

More News on Solara Active Pharma Sciences

1 Year Returns:-1.09%